Notice of Consultation on the Prescription Drug List: Tramadol

April 24, 2019
Our file number: 19- 109012-92

The Prescription Drug List (PDL) is a list of medicinal ingredients that when found in a drug, require a prescription. It does not include medicinal ingredients that are listed in Controlled Drugs and Substances Act Schedules. Recently, Health Canada published in Canada Gazette, Part I its intent to add tramadol to Schedule I to the Controlled Drugs and Substances Act (CDSA) and to the Narcotic Control Regulations (NCR). Should these additions occur, Health Canada would remove tramadol from the PDL.

The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to remove tramadol from the PDL should the above-mentioned additions occur to the CDSA and NCR.

Interested parties are encouraged to provide comments and suggestions by following the instructions provided in the Regulatory Impact Assessment Summary (RIAS) of the Canada Gazette Part I pre-publication.

Should you have any questions about this Notice of Consultation please contact:

Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9

Email: hc.drug.prescription.status-statut.dordonnance.des.drogues.sc@canada.ca
Telephone: 343-998-9304
Facsimile: 613-941-1812